Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial

By afschroeder • June 23, 2026

Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li D, Hamidi H, Penuel E, Janousek M, Wei MC, Batlevi C, Ead W, Sellam G, Horowitz NA. Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial. Blood Neoplasia. 2026 May 16;3(3):100248. doi: 10.1016/j.bneo.2026.100248. PMID: 42327599; PMCID: PMC13276744.

Tags: Hematology/Oncology, Publications

Personalizing cancer care for older adults

Ji J, Sedrak MS. Personalizing cancer care for older adults. J Gerontol A Biol Sci Med Sci. 2026 Jun 6;81(7):glag126. doi: 10.1093/gerona/glag126. PMID: 42329168; PMCID:[...]

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer

Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors[...]

Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology

Misic A, Ghanem G, Sadeghi S, Carroll M. Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology. Thromb J.[...]